Key Takeaways
- • CVC Capital Partners is pursuing a €10.9 billion ($12.6 billion) non-binding takeover offer for Italian pharmaceutical company Recordati at €52 per share, intending to delist the company from the Italian stock exchange.
- • CVC, which already owns 46.8% of Recordati, is actively seeking co-investors to help fund the transaction, with initial discussions underway with potential partners including GBL, ADIA, GIC, and CDPQ.
- • The deal requires approximately €5.5 billion to €6 billion in equity capital and remains subject to completion of due diligence, financing confirmation, and partner identification before proceeding.
- • Recordati shares gained significantly on confirmation of the offer, trading up 5.5% at €48.82 following the announcement, reflecting investor optimism about the proposed transaction.
- • CVC has preliminary plans to explore potential asset sales post-acquisition as part of its broader strategy for the drugmaker's portfolio optimization.
Summary
CVC Capital Partners has made a non-binding full takeover offer for Recordati SpA, the Italian pharmaceutical group, valuing the company at €10.9 billion (approximately $12.6 billion) at a preliminary offer price of €52 per share. According to Reuters reporting on March 26, Recordati confirmed receipt of the offer, which CVC submitted in writing to the company's board. The proposal is contingent on multiple conditions, including satisfactory completion of due diligence, securing financing arrangements, and identifying partners to co-invest in the transaction.
CVC currently holds a 46.8% stake in Recordati and is actively seeking co-investors to co-finance the acquisition. The financial newspaper Il Sole 24 Ore reported that CVC has initiated preliminary discussions with institutional investors regarding partnership opportunities. Identified potential partners include major global institutional investors such as GBL, ADIA, GIC, and CDPQ. The transaction structure requires approximately €5.5 billion to €6 billion in fresh equity capital to complete the full acquisition and delist the company.
Market reaction to the confirmed bid was positive. Recordati shares extended gains following the announcement, trading up 5.5% at €48.82 per share in the immediate aftermath. The offer represents a significant premium relative to prevailing market prices and reflects CVC's commitment to taking the company private as part of a longer-term ownership strategy.
CVC has also begun preliminary considerations regarding potential post-acquisition asset optimization strategies, with sources indicating the firm may explore selective asset sales to enhance portfolio returns and operational efficiency. These considerations remain preliminary and are contingent upon successful deal closure and subsequent integration planning.
CVC currently holds a 46.8% stake in Recordati and is actively seeking co-investors to co-finance the acquisition. The financial newspaper Il Sole 24 Ore reported that CVC has initiated preliminary discussions with institutional investors regarding partnership opportunities. Identified potential partners include major global institutional investors such as GBL, ADIA, GIC, and CDPQ. The transaction structure requires approximately €5.5 billion to €6 billion in fresh equity capital to complete the full acquisition and delist the company.
Market reaction to the confirmed bid was positive. Recordati shares extended gains following the announcement, trading up 5.5% at €48.82 per share in the immediate aftermath. The offer represents a significant premium relative to prevailing market prices and reflects CVC's commitment to taking the company private as part of a longer-term ownership strategy.
CVC has also begun preliminary considerations regarding potential post-acquisition asset optimization strategies, with sources indicating the firm may explore selective asset sales to enhance portfolio returns and operational efficiency. These considerations remain preliminary and are contingent upon successful deal closure and subsequent integration planning.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.